95333-96-3

Upstream product

• 20595-54-4 3,5-dichloro-cis-cinnamic acid 
• 220707-99-3 3-(3,5-dichlorophenyl)prop-2-yn-1-ol 
• 20595-53-3 3-(3,5-dichlorophenyl)-2-propenoic acid 
• 10203-08-4 3,5-dichlorobenzaldehyde 
• 95333-95-2 3-(3',5'-dichlorophenyl)propanoic acid 

Downstream Products

• 257889-73-9 1-(3-bromopropyl)-3,5-dichlorobenzene 
• 95333-82-7 1-[3-(3,5-dichlorophenyl)propyl]imidazole-2-thione 
• 101913-07-9 N-<3-(3,5-dichlorophenyl)propyl>aminoacetaldehyde dimethyl acetal 
• 95333-97-4 3-(3,5-dichlorophenyl)propan-1-al 

Relevant academic research and scientific papers

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

Method for treating glaucoma

Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1

Dopamine-β-hydroxylase inhibitors and use thereof

The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-β-hydroxylase inhibitors.